JP2024513972A5 - - Google Patents
Info
- Publication number
- JP2024513972A5 JP2024513972A5 JP2023562698A JP2023562698A JP2024513972A5 JP 2024513972 A5 JP2024513972 A5 JP 2024513972A5 JP 2023562698 A JP2023562698 A JP 2023562698A JP 2023562698 A JP2023562698 A JP 2023562698A JP 2024513972 A5 JP2024513972 A5 JP 2024513972A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- nucleotide
- acid according
- sense strand
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174507P | 2021-04-13 | 2021-04-13 | |
| US63/174,507 | 2021-04-13 | ||
| PCT/US2022/024692 WO2022221457A1 (en) | 2021-04-13 | 2022-04-13 | Rna silencing agents and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513972A JP2024513972A (ja) | 2024-03-27 |
| JP2024513972A5 true JP2024513972A5 (enExample) | 2025-04-09 |
Family
ID=83639690
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562698A Pending JP2024513972A (ja) | 2021-04-13 | 2022-04-13 | Ｒｎａサイレンシング剤および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240191229A1 (enExample) |
| EP (1) | EP4323376A4 (enExample) |
| JP (1) | JP2024513972A (enExample) |
| CN (1) | CN117425664A (enExample) |
| AU (1) | AU2022257002A1 (enExample) |
| CA (1) | CA3216732A1 (enExample) |
| WO (1) | WO2022221457A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| US20240401045A1 (en) * | 2021-10-01 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Angiotensinogen-modulating compositions and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8188060B2 (en) * | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| KR101728655B1 (ko) * | 2008-12-18 | 2017-04-19 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| EP2264169A1 (en) * | 2009-06-15 | 2010-12-22 | Qiagen GmbH | Modified siNA |
| US9243246B2 (en) * | 2010-08-24 | 2016-01-26 | Sirna Therapeutics, Inc. | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
| KR101696704B1 (ko) * | 2013-12-17 | 2017-01-16 | 주식회사 인코드젠 | 오프-타겟을 막기 위해 변형된 rna 간섭 유도 핵산 및 그 용도 |
| EP3736334A1 (en) * | 2014-07-16 | 2020-11-11 | Arrowhead Pharmaceuticals, Inc. | Rnai compositions to treat apoc3-related diseases |
| EP3234134B1 (en) * | 2014-12-17 | 2020-05-27 | ProQR Therapeutics II B.V. | Targeted rna editing |
-
2022
- 2022-04-13 JP JP2023562698A patent/JP2024513972A/ja active Pending
- 2022-04-13 CN CN202280034139.0A patent/CN117425664A/zh active Pending
- 2022-04-13 WO PCT/US2022/024692 patent/WO2022221457A1/en not_active Ceased
- 2022-04-13 EP EP22788889.8A patent/EP4323376A4/en active Pending
- 2022-04-13 CA CA3216732A patent/CA3216732A1/en active Pending
- 2022-04-13 AU AU2022257002A patent/AU2022257002A1/en active Pending
- 2022-04-13 US US18/286,640 patent/US20240191229A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113994000B (zh) | 包括胞苷类似物的反义rna编辑寡核苷酸 | |
| CA2184375C (en) | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties | |
| JP2007529224A5 (enExample) | ||
| US5726297A (en) | Oligodeoxyribonucleotide N3' P5' phosphoramidates | |
| CA2924186C (en) | Highly efficient synthesis of long rna using reverse direction approach | |
| JP2022528840A5 (enExample) | ||
| JP2005524393A5 (enExample) | ||
| JP2024513972A5 (enExample) | ||
| JP2021503941A5 (enExample) | ||
| JPH07501527A (ja) | 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形 | |
| Sharma et al. | Synthesis and biological properties of triazole-linked locked nucleic acid | |
| JP3653102B2 (ja) | 末端３′−３′および／または５′−５′連鎖を有するオリゴリボヌクレオチドおよびリボザイム類縁体 | |
| JP2009524419A5 (enExample) | ||
| EP3137606A1 (en) | METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT | |
| JP2008283975A5 (enExample) | ||
| PL169576B1 (pl) | Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| EP2256191A1 (en) | Cyclic single-stranded nucleic acid complex and method for producing the same | |
| RU2010112771A (ru) | Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки | |
| KR20260007576A (ko) | 변형된 가이드 rna | |
| JP2008500817A5 (ja) | Ｄｎａウイルスのマイクロｒｎａ及びそれを阻害する医薬品 | |
| Nurmi et al. | A modified X10-23 DNAzyme that can better access large, structured RNA targets | |
| JP2024522272A5 (enExample) | ||
| JP2022521502A5 (enExample) | ||
| Gotfredsen et al. | Novel oligodeoxynucleotide analogues containing a 2′-O-methylarabinonucleoside |